[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100542509":3},{"organization":4,"outcomesModule":7,"designInfo":38,"detailedDescription":11,"studyPopulation":11,"armGroups":44,"interventions":75,"overallOfficials":11,"centralContacts":81,"locations":87,"responsibleParty":194,"collaborators":196,"id":200,"slug":11,"hasResults":201,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":201,"sex":207,"minAge":208,"maxAge":11,"enrollmentInfo":209,"targetDuration":11,"studyType":212,"phases":213,"briefSummary":215,"conditions":216,"keywords":11,"overallStatus":152,"whyStopped":11,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":227},{"fullName":5,"class":6},"ReAlta Life Sciences, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Number of participants with treatment-related adverse events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)",null,"Day 1 to Day 180",{"measure":14,"description":11,"timeFrame":15},"Overall Response Rate (ORR) of RLS-0071","Day 1 to Day 28",[17,20,22,25,27,29,32,34,36],{"measure":18,"description":11,"timeFrame":19},"Incidence of refractoriness (to RLS-0071 +\u002F- ruxolitinib)","Days 7, 14, 28, 56, and 180",{"measure":21,"description":11,"timeFrame":19},"Overall corticosteroid use",{"measure":23,"description":11,"timeFrame":24},"Initiation of additional or alternative treatment(s) for aGvHD (including an increase in steroid dose to >2 mg\u002Fkg methylprednisolone equivalent)","Day 1 - Day 180",{"measure":26,"description":11,"timeFrame":19},"Change or shift in Stage for lower GI aGvHD, liver aGvHD, skin aGvHD, or upper GI aGvHD from baseline based on MAGIC Criteria",{"measure":28,"description":11,"timeFrame":19},"Attainment of Stage 0 or 1 lower GI aGvHD, liver aGvHD, skin aGvHD, or upper GI aGvHD",{"measure":30,"description":11,"timeFrame":31},"Change or shift in overall Grade of aGvHD","Day 0 - Days 7, 14, 28, 56, and 180.",{"measure":33,"description":11,"timeFrame":24},"Overall survival",{"measure":35,"description":11,"timeFrame":24},"Non-relapse mortality",{"measure":37,"description":11,"timeFrame":24},"Duration of hospital stay",{"allocation":39,"interventionModel":40,"interventionModelDescription":11,"primaryPurpose":41,"observationalModel":11,"timePerspective":11,"maskingInfo":42},"NON_RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":43,"maskingDescription":11,"whoMasked":11},"NONE",[45,51,55,59,63,67,71],{"label":46,"type":47,"description":48,"interventionNames":49},"RLS-0071Cohort 1","EXPERIMENTAL","10 mg\u002Fkg Q8H RLS-0071 for 7 days",[50],"Drug: RLS-0071",{"label":52,"type":47,"description":53,"interventionNames":54},"RLS-0071 Cohort 2","10 mg\u002Fkg Q8H RLS-0071 for 14 days with concurrent ruxolitinib",[50],{"label":56,"type":47,"description":57,"interventionNames":58},"RLS-0071 Cohort 3","20 mg\u002Fkg Q8H RLS-0071 for 14 days with concurrent ruxolitinib",[50],{"label":60,"type":47,"description":61,"interventionNames":62},"RLS-0071 Cohort 4","10 mg\u002Fkg Q8H RLS-0071 for 7 days and then 10 mg\u002Fkg QD RLS-0071 for 7 days with concurrent ruxolitinib",[50],{"label":64,"type":47,"description":65,"interventionNames":66},"RLS-0071 Cohort 5","20 mg\u002Fkg Q8H RLS-0071 for 7 days and then 20 mg\u002Fkg QD RLS-0071 for 7 days with concurrent ruxolitinib",[50],{"label":68,"type":47,"description":69,"interventionNames":70},"RLS-0071 Expansion Cohort 1","12 participants will receive 10 mg\u002Fkg Q8H RLS-0071 for 14 days",[50],{"label":72,"type":47,"description":73,"interventionNames":74},"RLS-0071 Expansion Cohort 2","12 participants will receive 20 mg\u002Fkg Q8H RLS-0071 for 14 days",[50],[76],{"type":77,"name":78,"description":79,"armGroupLabels":80,"otherNames":11},"DRUG","RLS-0071","RLS-0071 will be administered for 7 or 14 days according to the assigned dose group.",[52,56,60,64,68,72,46],[82],{"name":83,"role":84,"phone":85,"phoneExt":11,"email":86},"Linda Dell, MBA","CONTACT","201-675-4044","ldell@realtals.com",[88,102,111,121,131,141,150,162,174,182,190],{"facility":89,"status":90,"city":91,"state":92,"zip":93,"country":94,"countryCode":95,"cosmosGeoPoint":96,"geoPoint":101,"contacts":11},"Site 1091","ACTIVE_NOT_RECRUITING","Duarte","California","91010","United States","US",{"type":97,"coordinates":98},"Point",[99,100],-117.97729,34.13945,{"lat":100,"lon":99},{"facility":103,"status":90,"city":104,"state":92,"zip":105,"country":94,"countryCode":95,"cosmosGeoPoint":106,"geoPoint":110,"contacts":11},"Site 1343","Los Angeles","90095",{"type":97,"coordinates":107},[108,109],-118.24368,34.05223,{"lat":109,"lon":108},{"facility":112,"status":90,"city":113,"state":114,"zip":115,"country":94,"countryCode":95,"cosmosGeoPoint":116,"geoPoint":120,"contacts":11},"Site 1318","Atlanta","Georgia","30041",{"type":97,"coordinates":117},[118,119],-84.38798,33.749,{"lat":119,"lon":118},{"facility":122,"status":90,"city":123,"state":124,"zip":125,"country":94,"countryCode":95,"cosmosGeoPoint":126,"geoPoint":130,"contacts":11},"Site 1068","St Louis","Missouri","63110",{"type":97,"coordinates":127},[128,129],-90.19789,38.62727,{"lat":129,"lon":128},{"facility":132,"status":90,"city":133,"state":134,"zip":135,"country":94,"countryCode":95,"cosmosGeoPoint":136,"geoPoint":140,"contacts":11},"Site 1100","Cincinnati","Ohio","45229",{"type":97,"coordinates":137},[138,139],-84.51439,39.12711,{"lat":139,"lon":138},{"facility":142,"status":90,"city":143,"state":134,"zip":144,"country":94,"countryCode":95,"cosmosGeoPoint":145,"geoPoint":149,"contacts":11},"Site 1382","Columbus","43210",{"type":97,"coordinates":146},[147,148],-82.99879,39.96118,{"lat":148,"lon":147},{"facility":151,"status":152,"city":153,"state":11,"zip":154,"country":155,"countryCode":156,"cosmosGeoPoint":157,"geoPoint":161,"contacts":11},"Site 3242","RECRUITING","Freiburg im Breisgau","79106","Germany","DE",{"type":97,"coordinates":158},[159,160],7.85222,47.9959,{"lat":160,"lon":159},{"facility":163,"status":152,"city":164,"state":165,"zip":166,"country":167,"countryCode":168,"cosmosGeoPoint":169,"geoPoint":173,"contacts":11},"Site 3101","Seville","SE","41013","Spain","ES",{"type":97,"coordinates":170},[171,172],-5.97317,37.38283,{"lat":172,"lon":171},{"facility":175,"status":152,"city":176,"state":11,"zip":11,"country":167,"countryCode":168,"cosmosGeoPoint":177,"geoPoint":181,"contacts":11},"Site 3360","Madrid",{"type":97,"coordinates":178},[179,180],-3.70256,40.4165,{"lat":180,"lon":179},{"facility":183,"status":152,"city":184,"state":11,"zip":11,"country":167,"countryCode":168,"cosmosGeoPoint":185,"geoPoint":189,"contacts":11},"Site 3227","Salamanca",{"type":97,"coordinates":186},[187,188],-3.67975,40.42972,{"lat":188,"lon":187},{"facility":163,"status":152,"city":164,"state":11,"zip":11,"country":167,"countryCode":168,"cosmosGeoPoint":191,"geoPoint":193,"contacts":11},{"type":97,"coordinates":192},[171,172],{"lat":172,"lon":171},{"type":195,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[197],{"name":198,"class":199},"CTI Clinical Trial and Consulting Services","OTHER","100542509",false,"NCT06343792","Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease","Phase 2 Open Label Prospective Dose-Ranging Clinical Trial With Escalation and Expansion Cohorts to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease","AURORA","Inclusion Criteria:\n\n* Male or female adults or adolescents (\\>12 years old).\n* Hospitalized with steroid-refractory aGvHD (grade II-IV) after allo-HSCT\n* Anticipated hospital length-of-stay of at least 1 week from the time of RLS-0071 initiation.\n* No plans to add additional GvHD treatment medications or to add, dose-adjust, or discontinue GvHD prophylactic medications during the 7-days of RLS-0071 treatment.\n* Neutrophil recovery following the stem-cell transplantation, defined as blood neutrophil count \\>500\u002FmL for at least 3 consecutive measurements and not supported by growth factor supplementation\n* Weight ≥40 kg and ≤ 140 kg at screening.\n\nExclusion Criteria:\n\n* Has received more than 1 allo-HSCT\n* Current, previous, or planned use of any systemic treatment in addition to or other than corticosteroids or ruxolitinib for aGvHD\n* Previous failure of ruxolitinib treatment\n* Uncontrolled GI infection\n* Endoscopic and biopsy testing (if performed) that definitively rules out lower GI aGvHD\n* Chronic GvHD\n* Participants with evidence of relapsed primary disease, or participants who have been treated for relapse after the allo-HSCT was performed.\n* Unresolved toxicity or complications (other than aGvHD) due to the allo-HSCT\n* Any corticosteroid therapy for indications other than aGvHD at doses of methylprednisolone or equivalent \\>1 mg\u002Fkg per day within 7 days of enrollment.\n* Severe organ dysfunction unrelated to underlying aGvHD\n* Known hypersensitivity, allergy, or anaphylactic reaction to polyethylene glycol (PEG)\n* Significant liver disease that is unrelated to GvHD\n* Severe kidney disease\n* Currently breast feeding.\n* Known pregnancy, a positive pregnancy test at screening, or lactation for WOCBP.\n* Active hepatitis B virus (HBV) or hepatitis C virus infection that requires treatment or human immunodeficiency virus (HIV)-1 or HIV-2.\n* Active sepsis","ALL","12 Years",{"count":210,"type":211},66,"ESTIMATED","INTERVENTIONAL",[214],"PHASE2","This study is a Open Label Prospective Dose-Ranging Escalation and Expansion Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the secondary treatment of acute Graft-versus-Host Disease (aGvHD) in hospitalized patients who are steroid-refractory.",[217],"Steroid Refractory GVHD","2025-11-18",{"date":220,"type":221},"2025-11-24","ACTUAL",{"date":223,"type":221},"2024-08-31",{"date":225,"type":211},"2026-12",{"name":5,"class":6},11]